Baird Rates Nurix Therapeutics (NRIX) buy, $33 Price Target

Wall Street firms keep active coverage on Nurix Therapeutics as the stock trades well below analyst price targets, a 76.23% upside from the current price.

By TradeTexts Research Desk · Published Jun 18, 2026, 10:01 AM EDT · Updated Jun 24, 2026, 10:03 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Baird rated Nurix Therapeutics, Inc. ($NRIX) "buy" with a $33 price target on June 18, 2026.

Since the rating, $NRIX is up 28.0% after 1 week, up 29.4% after 1 month and up 39.1% to date (from the $17.55 close on Jun 18, 2026).

NRIX Nurix Therapeutics, Inc.

$24.42 +35.22% year to date

Daily close · Oct 16, 2026

Key Points

Nurix Therapeutics, Inc. trades at $18.73 on the NasdaqGM while analysts maintain a consensus mean price target of $33.93 across fourteen opinions.
Baird's $33 price target implies 76.23% upside from Nurix Therapeutics, Inc.'s ($NRIX) current $18.73 share price.
Chief Scientific Officer Hansen Gwenn sold 1,452 shares on October 15, 2026, at an average price of $25.00 under a pre-arranged trading plan.
Wall Street firms including H.C. Wainwright & Co., RBC Capital, and Oppenheimer recently updated their targets and ratings for the biotechnology firm.

Get $NRIX trade alerts by text

We text you when insiders, Congress or big funds trade $NRIX. Free.

Not investment advice. TradeTexts is not a registered investment adviser, and this automated Nurix Therapeutics, Inc. alert may contain errors. Disclosures

Nurix Therapeutics Stock Price and Target Gap

Nurix Therapeutics, Inc. shares change hands around $18.73 on the NasdaqGM, leaving a notable gap between the current market price and Wall Street expectations. Analyst Joel Beatty at Baird reiterated a buy rating on the biotechnology firm on June 18, 2026, alongside a $33.00 price target. Across fourteen analyst opinions, the stock holds a consensus mean price target of $33.93, with individual targets ranging from a low of $25.00 to a high of $45.00. This setup places the market value well beneath the average target set by covering financial institutions.

12-month forecast

$NRIX price target

Nurix Therapeutics, Inc. daily closes and this analyst's $33 target. Not advice.

Wall Street Analyst Coverage and Firm Targets

Financial institutions continue to monitor the biotechnology company with active rating updates and price adjustments. On October 16, 2026, H.C. Wainwright & Co. maintained a buy rating while raising its price target to $36.00 from $34.00. Earlier in October, RBC Capital maintained an outperform rating with a $35.00 target on October 13, 2026, while Oppenheimer kept an outperform rating with a $32.00 target. Truist Securities maintained a buy rating with a $33.00 target on October 13, 2026, and Baird maintained an outperform rating with a $36.00 target on the same day. Needham reiterated a buy rating with a $34.00 target.

Insider Buying and Selling at Nurix Therapeutics, Inc.

Corporate insiders have also adjusted their holdings during the autumn filing period. Chief Scientific Officer Hansen Gwenn sold 1,452 shares of the firm on October 15, 2026, for a total value of $36,300.00 at an average price of $25.00. The transaction was carried out under a pre-arranged Rule 10b5-1 trading plan, which allows company insiders to set up automated stock sales ahead of time.

Biotechnology Pipeline and Corporate Focus

Nurix Therapeutics, Inc. focuses on discovering, developing, and commercializing small molecule and antibody therapies to treat cancer, inflammatory conditions, and other diseases. The Brisbane, California-based enterprise develops targeted protein degraders, including clinical-stage candidates designed to address relapsed or refractory B-cell malignancies and autoimmune disorders. The organization maintains strategic collaboration agreements with major pharmaceutical partners for co-development work.

What to Watch Next for NRIX

Investors are keeping an eye on the company's upcoming earnings report scheduled for October 8, 2026, which will provide fresh data on financial performance, research spending, and clinical trial progress. Market participants will also monitor any subsequent analyst adjustments or additional insider filing reports from the biotechnology firm.